StreetInsider.com News Articles

Telsey analyzes GLP-1 drugs' impact on consumer sector

Tue, 20 Oct 2026 07:50:49 -0400

Investing.com -- Telsey released a report examining how GLP-1 medications are affecting consumer spending patterns across multiple retail categories. The drugs, first approved by the FDA in 2005 for type 2 diabetes treatment, have gained widespread adoption in recent years.

GLP-1 medications include semaglutide, sold as Ozempic and Rybelsus for diabetes and Wegovy for obesity, and tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity. The drugs work by stimulating insulin release, reducing blood sugar, slowing digestion, and reducing hunger.

Companies covered by Telsey have reported changes in consumer behavior related to GLP-1 use, including purchases of new wardrobes, products to

Telsey analyzes GLP-1 drugs' impact on consumer sector

Tue, 20 Oct 2026 07:50:49 -0400

Companies covered by Telsey have reported changes in consumer behavior related to GLP-1 use, including purchases of new wardrobes, products to

Telsey analyzes GLP-1 drugs' impact on consumer sector

Tue, 20 Oct 2026 07:50:49 -0400

Companies covered by Telsey have reported changes in consumer behavior related to GLP-1 use, including purchases of new wardrobes, products to

Telsey analyzes GLP-1 drugs' impact on consumer sector

Tue, 20 Oct 2026 07:50:49 -0400

Companies covered by Telsey have reported changes in consumer behavior related to GLP-1 use, including purchases of new wardrobes, products to

Form SCHEDULE 13G/A ELI LILLY & Co Filed by: LILLY ENDOWMENT INC

Mon, 19 Oct 2026 15:09:00 -0400

si-local-file:///var/storage/secattach/20261019/27203477.html

Lilly's Omvoh meets primary endpoint in pediatric colitis trial

Mon, 19 Oct 2026 04:40:17 -0400

Eli Lilly and Company (NYSE: LLY) reported positive one-year results from its Phase 3 SHINE-2 study of Omvoh (mirikizumab-mrkz) in pediatric patients ages 6 to 17 with moderately to severely active ulcerative colitis, according to a company press release.

In the single-arm, open-label study, 81% of patients achieved clinical response to Omvoh induction at Week 12. Among those responders, 50% achieved clinical remission at Week 52, meeting the study's primary endpoint. Lilly claims Omvoh is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis.

Additional Week 52 outcomes among Week 12 responders included 73.1% clinical response, 71.2%

Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis

Mon, 19 Oct 2026 04:40:00 -0400

Building on Omvoh's approved use and durable efficacy in adults, Lilly plans to submit these data to global regulators to support a potential label expansion for pediatric ulcerative colitis

More than 80% of patients responded to Omvoh induction, and half of responders, ages 6 to 17, were in clinical remission at one year in Phase 3 SHINE-2 study

Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis

Mon, 19 Oct 2026 04:40:00 -0400

Building on Omvoh's approved use and durable efficacy in adults, Lilly plans to submit these data to global regulators to support a potential label expansion for pediatric ulcerative colitis

More than 80% of patients responded to Omvoh induction, and half of responders, ages 6 to 17, were in clinical remission at one year in Phase 3 SHINE-2 study

Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress

Sun, 18 Oct 2026 18:05:00 -0400

First Phase 1 data for sofetabart mipitecan, Lilly's investigational FRα-targeting ADC, in platinum-sensitive ovarian cancer to be featured in a rapid oral presentation

Updated first-line data for olomorasib, an investigational therapy targeting KRAS G12C-mutant NSCLC, to be featured in a rapid oral presentation

Updated Phase 3 data for

Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress

Sun, 18 Oct 2026 18:05:00 -0400

First Phase 1 data for sofetabart mipitecan, Lilly's investigational FRα-targeting ADC, in platinum-sensitive ovarian cancer to be featured in a rapid oral presentation

Updated first-line data for olomorasib, an investigational therapy targeting KRAS G12C-mutant NSCLC, to be featured in a rapid oral presentation

Updated Phase 3 data for

Form 144 ELI LILLY & Co Filed by: LILLY ENDOWMENT INC

Thu, 15 Oct 2026 14:44:00 -0400
si-local-file:///var/storage/secattach/20261015/27192921.html

Lilly confirms date and conference call for third-quarter 2026 financial results announcement

Thu, 15 Oct 2026 10:00:00 -0400

INDIANAPOLIS, Oct. 15, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2026 financial results on October 29, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.

The conference call will begin at 10 a.m. Eastern time. Investors, media and

Lilly confirms date and conference call for third-quarter 2026 financial results announcement

Thu, 15 Oct 2026 10:00:00 -0400

INDIANAPOLIS, Oct. 15, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2026 financial results on October 29, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.

The conference call will begin at 10 a.m. Eastern time. Investors, media and

Lilly's Omvoh shows composite disease control in bowel disease trials

Thu, 15 Oct 2026 08:01:53 -0400

Eli Lilly and Company (NYSE: LLY) released post-hoc data showing that patients with ulcerative colitis (UC) and Crohn's disease treated with Omvoh (mirikizumab-mrkz) achieved multiple treatment goals simultaneously at one year, according to analyses from the LUCENT and VIVID clinical trial programs.
In the LUCENT-2 maintenance study, 27.7% of Omvoh-treated UC patients achieved comprehensive disease control — a composite outcome combining symptomatic, endoscopic and histologic remission, biomarker normalization and no corticosteroid use — compared with 14% of placebo recipients. Among patients with prior biologic failure, 23.4% of those on Omvoh achieved this outcome versus 9.4% on placebo. More than one-third of

Lilly's Omvoh shows composite disease control in bowel disease trials

Thu, 15 Oct 2026 08:01:53 -0400

Eli Lilly and Company (NYSE: LLY) released post-hoc data showing that patients with ulcerative colitis (UC) and Crohn's disease treated with Omvoh (mirikizumab-mrkz) achieved multiple treatment goals simultaneously at one year, according to analyses from the LUCENT and VIVID clinical trial programs.
In the LUCENT-2 maintenance study, 27.7% of Omvoh-treated UC patients achieved comprehensive disease control — a composite outcome combining symptomatic, endoscopic and histologic remission, biomarker normalization and no corticosteroid use — compared with 14% of placebo recipients. Among patients with prior biologic failure, 23.4% of those on Omvoh achieved this outcome versus 9.4% on placebo. More than one-third of

New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep re

Thu, 15 Oct 2026 08:00:00 -0400

In LUCENT-2, more than one in four (27.7%) Omvoh-treated patients with ulcerative colitis achieved comprehensive disease control, a novel composite outcome defined by simultaneous symptomatic, endoscopic and histologic remission, biomarker normalization and no corticosteroid use

In VIVID-1, one in five (20.4%) Omvoh-treated patients with Crohn's disease achieved corticosteroid-free deep remission, a composite outcome defined by simultaneous clinical remission, endoscopic remission and no corticosteroid use

New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep re

Thu, 15 Oct 2026 08:00:00 -0400

In LUCENT-2, more than one in four (27.7%) Omvoh-treated patients with ulcerative colitis achieved comprehensive disease control, a novel composite outcome defined by simultaneous symptomatic, endoscopic and histologic remission, biomarker normalization and no corticosteroid use

In VIVID-1, one in five (20.4%) Omvoh-treated patients with Crohn's disease achieved corticosteroid-free deep remission, a composite outcome defined by simultaneous clinical remission, endoscopic remission and no corticosteroid use

Nasdaq Sheds 1.65% as Russell 2000 Sinks to RSI 28, Oil Climbs While Gold and Silver Slide

Wed, 14 Oct 2026 13:39:00 -0400

Stock Preachers News Commentary

VANCOUVER, BC, Oct. 14, 2026 /PRNewswire/ -- Stocks skidded midweek as the Nasdaq Composite dropped 449 points, or 1.65%, to 26,755.24, pulling its weekly loss to 2.23%. The S&P 500 fell 1.10% on the day and 1.18% for the week, while the Russell 2000 tumbled 1.70% and now carries an RSI of just 28.3, signaling deeply

Nasdaq Sheds 1.65% as Russell 2000 Sinks to RSI 28, Oil Climbs While Gold and Silver Slide

Wed, 14 Oct 2026 13:39:00 -0400

Stock Preachers News Commentary

VANCOUVER, BC, Oct. 14, 2026 /PRNewswire/ -- Stocks skidded midweek as the Nasdaq Composite dropped 449 points, or 1.65%, to 26,755.24, pulling its weekly loss to 2.23%. The S&P 500 fell 1.10% on the day and 1.18% for the week, while the Russell 2000 tumbled 1.70% and now carries an RSI of just 28.3, signaling deeply

Nasdaq Sheds 1.65% as Russell 2000 Sinks to RSI 28, Oil Climbs While Gold and Silver Slide

Wed, 14 Oct 2026 13:39:00 -0400

Stock Preachers News Commentary

VANCOUVER, BC, Oct. 14, 2026 /PRNewswire/ -- Stocks skidded midweek as the Nasdaq Composite dropped 449 points, or 1.65%, to 26,755.24, pulling its weekly loss to 2.23%. The S&P 500 fell 1.10% on the day and 1.18% for the week, while the Russell 2000 tumbled 1.70% and now carries an RSI of just 28.3, signaling deeply

Nasdaq Sheds 1.65% as Russell 2000 Sinks to RSI 28, Oil Climbs While Gold and Silver Slide

Wed, 14 Oct 2026 13:39:00 -0400

Stock Preachers News Commentary

VANCOUVER, BC, Oct. 14, 2026 /PRNewswire/ -- Stocks skidded midweek as the Nasdaq Composite dropped 449 points, or 1.65%, to 26,755.24, pulling its weekly loss to 2.23%. The S&P 500 fell 1.10% on the day and 1.18% for the week, while the Russell 2000 tumbled 1.70% and now carries an RSI of just 28.3, signaling deeply

Nasdaq Sheds 1.65% as Russell 2000 Sinks to RSI 28, Oil Climbs While Gold and Silver Slide

Wed, 14 Oct 2026 13:39:00 -0400

Stock Preachers News Commentary

VANCOUVER, BC, Oct. 14, 2026 /PRNewswire/ -- Stocks skidded midweek as the Nasdaq Composite dropped 449 points, or 1.65%, to 26,755.24, pulling its weekly loss to 2.23%. The S&P 500 fell 1.10% on the day and 1.18% for the week, while the Russell 2000 tumbled 1.70% and now carries an RSI of just 28.3, signaling deeply

Nasdaq Sheds 1.65% as Russell 2000 Sinks to RSI 28, Oil Climbs While Gold and Silver Slide

Wed, 14 Oct 2026 13:39:00 -0400

Stock Preachers News Commentary

VANCOUVER, BC, Oct. 14, 2026 /PRNewswire/ -- Stocks skidded midweek as the Nasdaq Composite dropped 449 points, or 1.65%, to 26,755.24, pulling its weekly loss to 2.23%. The S&P 500 fell 1.10% on the day and 1.18% for the week, while the Russell 2000 tumbled 1.70% and now carries an RSI of just 28.3, signaling deeply

Nasdaq Sheds 1.65% as Russell 2000 Sinks to RSI 28, Oil Climbs While Gold and Silver Slide

Wed, 14 Oct 2026 13:39:00 -0400

Stock Preachers News Commentary

VANCOUVER, BC, Oct. 14, 2026 /PRNewswire/ -- Stocks skidded midweek as the Nasdaq Composite dropped 449 points, or 1.65%, to 26,755.24, pulling its weekly loss to 2.23%. The S&P 500 fell 1.10% on the day and 1.18% for the week, while the Russell 2000 tumbled 1.70% and now carries an RSI of just 28.3, signaling deeply

Nasdaq Sheds 1.65% as Russell 2000 Sinks to RSI 28, Oil Climbs While Gold and Silver Slide

Wed, 14 Oct 2026 13:39:00 -0400

Stock Preachers News Commentary

VANCOUVER, BC, Oct. 14, 2026 /PRNewswire/ -- Stocks skidded midweek as the Nasdaq Composite dropped 449 points, or 1.65%, to 26,755.24, pulling its weekly loss to 2.23%. The S&P 500 fell 1.10% on the day and 1.18% for the week, while the Russell 2000 tumbled 1.70% and now carries an RSI of just 28.3, signaling deeply